期刊
ANNALS OF ONCOLOGY
卷 24, 期 6, 页码 1587-1593出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdt070
关键词
dose-intensive; mantle cell; rituximab
类别
资金
- NIH [CA32102]
Background: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibility in a multicenter study that includes both academic and community-based practices, a phase II study of this regimen was conducted by SWOG. Patients and methods: Forty-nine patients with advanced stage, previously untreated MCL were eligible. The median age was 57.4 years (35-69.8 years). Results: Nineteen patients (39%) did not complete the full scheduled course of treatment due to toxicity. There was one treatment-related death and two cases of secondary myelodysplastic syndrome (MDS). There were 10 episodes of grade 3 febrile neutropenia, 19 episodes of grade 3 and 1 episode of grade 4 infection. With a median follow-up of 4.8 years, the median progression-free survival was 4.8 years (5.5 years for those <= 65 years) and the median overall survival (OS) was 6.8 years. Conclusions: Although this regimen is toxic, it is active for patients <= 65 years of age and can be given both at academic centers and in experienced community centers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据